Ed Hurwitz is the Founding Managing Director of Precision Bioventures (PBV), a consulting and investment advisory firm dedicated to investing in and building innovative biomedical companies at all stages of development. Ed currently serves as Chairman of the Board of Viewpoint Therapeutics and is a member of the Board of Directors of MacroGenics, Inc. and AGTC Therapeutics. Prior to founding PBV, Ed was a General Partner at Alta Partners, a life sciences venture capital firm. While at Atla, Ed led investments in AGTC (AGTC), Avid Radiopharmaceuticals (Sold to Eli Lilly), Calistoga Pharmaceuticals (sold to Gilead), Cara Therapeutics (CARA), Chemocentryx, Inc. (CCXI), FoldRx, Inc. (Sold to Pfizer), MacroGenics, Inc. (MGNX), Repros Therapeutics, Inc. (RPRX), Sunesis Pharmaceuticals, Inc. (SNSS), Taligen Therapeutics (Sold to Alexion) and Zafgen, Inc. (ZFGN). Prior to joining Alta, Ed was a senior vice president and CFO at Affymetrix, Inc. Ed was also a sell side analyst at Robertson Stephens and Co and Smith Barney Shearson. Ed began his professional career as an attorney at Cooley Godward. Ed holds a JD degree from UC’s Berkeley’s Boalt School of Law, an MBA from UC Berkeley’s Haas School of Business and a BA from Cornell University.